Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Interest Expenses (2024 - 2025)

OptimizeRx (OPRX) has disclosed Interest Expenses for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 20.6% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.3 million through Dec 2025, down 14.06% year-over-year, with the annual reading at $5.3 million for FY2025, 14.06% down from the prior year.
  • Interest Expenses hit $1.2 million in Q4 2025 for OptimizeRx, up from $1.2 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.6 million in Q2 2025 to a low of $1.2 million in Q3 2025.